Aduhelm (aducanumab-avwa) is an amyloid beta-directed antibody used to treat people with mild cognitive impairment or mild dementia.1 It is the first novel therapy approved for Alzheimer’s disease since 2003, and the first disease-modifying therapy for Alzheimer’s, targeting the underlying cause of Alzheimer’s disease, the presence of amyloid beta plaques in the brain.1 It is available in vial form for intravenous infusion, containing either 170 mg/1.7 mL (100 mg/mL) and 300 mg/3 mL (100 mg/mL) aducanumab-avwa.1